These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 32185137)

  • 21. Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study.
    Lepretre S; Touzart A; Vermeulin T; Picquenot JM; Tanguy-Schmidt A; Salles G; Lamy T; Béné MC; Raffoux E; Huguet F; Chevallier P; Bologna S; Bouabdallah R; Benichou J; Brière J; Moreau A; Tallon-Simon V; Seris S; Graux C; Asnafi V; Ifrah N; Macintyre E; Dombret H
    J Clin Oncol; 2016 Feb; 34(6):572-80. PubMed ID: 26644537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel biological insights in T-cell acute lymphoblastic leukemia.
    Durinck K; Goossens S; Peirs S; Wallaert A; Van Loocke W; Matthijssens F; Pieters T; Milani G; Lammens T; Rondou P; Van Roy N; De Moerloose B; Benoit Y; Haigh J; Speleman F; Poppe B; Van Vlierberghe P
    Exp Hematol; 2015 Aug; 43(8):625-39. PubMed ID: 26123366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.
    Lonetti A; Cappellini A; Bertaina A; Locatelli F; Pession A; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; Zambonin L; Neri LM; Martelli AM; Chiarini F
    J Hematol Oncol; 2016 Oct; 9(1):114. PubMed ID: 27776559
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols.
    Zuurbier L; Homminga I; Calvert V; te Winkel ML; Buijs-Gladdines JG; Kooi C; Smits WK; Sonneveld E; Veerman AJ; Kamps WA; Horstmann M; Petricoin EF; Pieters R; Meijerink JP
    Leukemia; 2010 Dec; 24(12):2014-22. PubMed ID: 20861909
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia.
    Canté-Barrett K; Spijkers-Hagelstein JA; Buijs-Gladdines JG; Uitdehaag JC; Smits WK; van der Zwet J; Buijsman RC; Zaman GJ; Pieters R; Meijerink JP
    Leukemia; 2016 Sep; 30(9):1832-43. PubMed ID: 27174491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances of target therapy on NOTCH1 signaling pathway in T-cell acute lymphoblastic leukemia.
    Zheng R; Li M; Wang S; Liu Y
    Exp Hematol Oncol; 2020 Nov; 9(1):31. PubMed ID: 33292596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long non-coding RNA signatures and related signaling pathway in T-cell acute lymphoblastic leukemia.
    Yousefi H; Purrahman D; Jamshidi M; Lak E; Keikhaei B; Mahmoudian-Sani MR
    Clin Transl Oncol; 2022 Nov; 24(11):2081-2089. PubMed ID: 35852681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive view on genetic features, therapeutic modalities and prognostic models in adult T-cell lymphoblastic lymphoma.
    Zou Q; Ma S; Tian X; Cai Q
    Blood Sci; 2022 Jul; 4(3):155-160. PubMed ID: 36518593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia.
    Alameen AA; Simioni C; Martelli AM; Zauli G; Ultimo S; McCubrey JA; Gonelli A; Marisi G; Ulivi P; Capitani S; Neri LM
    Oncotarget; 2016 Aug; 7(34):55690-55703. PubMed ID: 27494886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.
    Cani A; Simioni C; Martelli AM; Zauli G; Tabellini G; Ultimo S; McCubrey JA; Capitani S; Neri LM
    Oncotarget; 2015 Mar; 6(9):6597-610. PubMed ID: 25788264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent Advances in the Biology and Treatment of T Cell Acute Lymphoblastic Leukemia.
    Hefazi M; Litzow MR
    Curr Hematol Malig Rep; 2018 Aug; 13(4):265-274. PubMed ID: 29948644
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early T-Cell Precursor Acute Lymphoblastic Leukemia: Diagnosis, Updates in Molecular Pathogenesis, Management, and Novel Therapies.
    Sin CF; Man PM
    Front Oncol; 2021; 11():750789. PubMed ID: 34912707
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of NRF2 Activation as a Prognostic Biomarker in T-Cell Acute Lymphoblastic Leukaemia.
    Villa-Morales M; Pérez-Gómez L; Pérez-Gómez E; López-Nieva P; Fernández-Navarro P; Santos J
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment.
    Demosthenous C; Lalayanni C; Iskas M; Douka V; Pastelli N; Anagnostopoulos A
    Curr Probl Cancer; 2019 Jun; 43(3):222-227. PubMed ID: 29895435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.
    Mendes RD; Canté-Barrett K; Pieters R; Meijerink JP
    Haematologica; 2016 Sep; 101(9):1010-7. PubMed ID: 27582570
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BCL11B, FLT3, NOTCH1 and FBXW7 mutation status in T-cell acute lymphoblastic leukemia patients.
    Kraszewska MD; Dawidowska M; Kosmalska M; Sędek L; Grzeszczak W; Kowalczyk JR; Szczepański T; Witt M;
    Blood Cells Mol Dis; 2013 Jan; 50(1):33-8. PubMed ID: 23040356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [PI3K/AKT/mTOR Pathway and Pediatric T Acute Lymphoblastic Leukemia-Review].
    Shi LX; Wang JH; Shi XD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1269-74. PubMed ID: 27531814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NOTCH1 and FBXW7 mutations favor better outcome in pediatric South Indian T-cell acute lymphoblastic leukemia.
    Natarajan V; Bandapalli OR; Rajkumar T; Sagar TG; Karunakaran N
    J Pediatr Hematol Oncol; 2015 Jan; 37(1):e23-30. PubMed ID: 25493453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting NOTCH1 in combination with antimetabolite drugs prolongs life span in relapsed pediatric and adult T-acute lymphoblastic leukemia xenografts.
    Minuzzo S; Agnusdei V; Pinazza M; Amaro AA; Sacchetto V; Pfeffer U; Bertorelle R; Spinelli O; Serafin V; Indraccolo S
    Exp Hematol Oncol; 2023 Sep; 12(1):76. PubMed ID: 37667380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response.
    Dixon ZA; Nicholson L; Zeppetzauer M; Matheson E; Sinclair P; Harrison CJ; Irving JA
    Haematologica; 2017 Apr; 102(4):736-745. PubMed ID: 27979926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.